Breakthrough drug pushed as standard treatment for dengue fever in Indonesia

Print

Breakthrough drug pushed as standard
treatment for dengue fever in Indonesia

INDONESIA: Results of a two year phase three human clinical trial into 98alive™’s efficacy in treating dengue fever have been so positive that experts are now suggesting the drug be adopted as the standard treatment for the deadly virus in Indonesia. Conducted by 12 leading scientists at Indonesia’s Airlangga University, the trial found the active ingredient in 98alive™ decreased the viral load of all four strains of dengue fever at a rate of 96.67%.
It’s a significant breakthrough in treating one of the world’s most prevalent communicable diseases, with the trial’s Principal Investigator Professor Nasronudin stating it’s achieved what many international health organisations have been trying for decades to do. “This finding is an innovation in treating dengue fever which up until now has had no vaccine or treatment therapy available,” Professor Nasronudin said. “Not only did it show 98alive™ has antiviral activity against the dengue virus, but results also indicate that it strengthens the immune system. Patients treated in the viral load group showed CD4 and CD8 cell together increase of around 64.4%.”
Privately funded by the product’s discoverer and developer, Australian based company 98 Alive Pty Ltd, the double-blind, randomised and placebo controlled trial involved 530 patients in whom dengue infection was shown by Ns-1, IgG and IgM positive detection.
It found that at a dosage of 300mg twice daily, 98alive™ significantly reduced the symptoms of dengue fever by day three, with symptoms having disappeared by day five. 98 Alive Director and product developer Professor Max Reynolds states the results of the trial, which was approved by the Medical Research Ethical Committee of Soetomo Hospital in Surabaya and supported by five hospitals and 10 primary health centres, prove it to be a viable treatment for dengue.
“We are strongly suggesting to the Indonesian government that 98alive™ be adopted as the standard treatment for all four strains of the dengue virus nationally,” he explained. “No other product has produced the same results that we have and with 98alive™ having no side effects, we can’t see any reason why it can’t be the primary treatment against dengue fever in Indonesia.”
A patented formulation of Melaleuca alternifolia leaf extract that uniquely contains 98 separate molecular structures, 98alive™ was developed by 98 Alive to strengthen the immune system against a number of diseases.(PR)